PHARMACEUTICAL major Lupin said on Thursday (3) it will foray into India's digital healthcare with a focus on providing a digital therapeutics platform for doctors and patients.
In a regulatory filing, the company said it recently incorporated a new entity, Lupin Digital Health Ltd, as a wholly owned subsidiary.
"...the board of directors has approved the company's entry into the digital healthcare space...," it said in the filing.
Lupin, however, did not share any other details about the new venture.
The company also launched Arformoterol Tartrate, an inhalation product, to treat conditions like chronic bronchitis and emphysema, in the US market today (4).
According to some reports, Lupin is working on acquiring licences and partnerships for various Covid-19 drugs and vaccines after the company missed out on launching drugs in the first wave of the coronavirus pandemic.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra.
The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the US, India, South Africa and across Asia Pacific, Latin America, Europe and Middle-East regions.
Shares of Lupin Ltd were trading 0.22 per cent higher at Rs 1,235 (£11.96) on BSE.
